Endpoints News, November 25, 2020. Three months after Reata Pharmaceuticals suggested its Friedreich’s ataxia program omaveloxolone could be delayed, the company revealed that is indeed going to be the case.
The FDA did not rule out reconsidering omaveloxolone’s application once the new study has been completed, Reata noted.